Intuitive Surgical, Inc.
ISRG scores 72.3 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.
Minor adjustments (-0.9 points) applied. ISRG's rank of #64 primarily reflects its factor profile relative to the conservative weight vector.
These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.
No risk factors identified.
| Stock | Score | P/E | Rev Growth | Margin | Mkt Cap |
|---|---|---|---|---|---|
| ISRG | 72.3 | 61.7 | 20.5% | 28.4% | $172.5B |
| INCY | 89.6 | 15.8 | 21.2% | 25.0% | $20.1B |
| GMAB | 85.5 | 13.1 | 22.8% | 36.4% | $18.5B |
| CPRX | 82.2 | 13.7 | 23.5% | 37.6% | $3.0B |
| VRTX | 78.0 | 32.1 | 8.9% | 32.9% | $126.0B |
| ASND | 75.7 | 16.6 | 98.0% | -31.7% | $13.3B |
| NBIX | 74.7 | 26.5 | 21.4% | 16.7% | $12.5B |
| ALKS | 74.6 | 16.5 | -6.4% | 23.9% | $5.5B |
| AMGN | 73.8 | 26.0 | 10.0% | 21.0% | $199.0B |
| ARGX | 73.6 | 35.1 | 78.6% | 38.0% | $50.9B |
| HOLX | 73.3 | 31.1 | 1.7% | 13.8% | $16.8B |
| REGN | 72.7 | 19.4 | 1.0% | 31.4% | $84.9B |
| EXEL | 71.9 | 15.1 | 7.0% | 33.7% | $11.7B |
| KRYS | 71.0 | 41.4 | 473.0% | 30.7% | $8.0B |
| HALO | 70.2 | 16.8 | 22.4% | 43.7% | $9.3B |
| BMRN | 69.7 | 22.3 | 18.0% | 15.0% | $11.5B |
| Sector Average | 37.1 | 252.3 | 161.5% | -3292.7% | â |
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System to enable complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its surgical systems; progressive learning pathways to support the use of its technology; a complement of services to its customers, including support, installation, repair, and maintenance; and integrated digital capabilities providing unified and connected offerings, streamlining performance for hospitals with program-enhancing insights. The company was incorporated in 1995 and is headquartered in Sunnyvale, California.
Stock is building a base after a decline. The 200-day moving average is flattening. Watch for a breakout above the 200-day SMA on increased volume.
| Metric | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|
| Revenue | $2.9B | $2.5B | $2.4B | $2.3B |
| Gross Profit | $1.9B | $1.7B | $1.6B | $1.5B |
| Operating Income | $864M | $760M | $743M | $578M |
| Net Income | $795M | $704M | $658M | $698M |
| EPS (Diluted) | $2.21 | $1.95 | $1.81 | $1.92 |
| Gross Margin | 66.4% | 66.4% | 66.3% | 64.7% |
| Operating Margin | 30.2% | 30.3% | 30.5% | 25.7% |
| Net Margin | 27.7% | 28.1% | 27.0% | 31.0% |
| Year | Low | High | Range | Status |
|---|---|---|---|---|
| 2021 | $227.47 | $369.69 | 47.6% | Wide |
| 2022 | $180.07 | $362.00 | 67.1% | Wide |
| 2023 | $222.65 | $358.07 | 46.6% | Wide |
| 2024 | $320.26 | $556.23 | 53.8% | Wide |
| 2025 | $425.00 | $616.00 | 36.7% | Wide |
Growth estimates have been dampened based on technical and fundamental signals. This is a post-hoc adjustment to prevent overly optimistic projections for stocks showing declining momentum or deteriorating fundamentals.
Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.